Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Starpharma Holdings Ltd

SPL.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Micro Cap Analyst: BUY

Last Close

$0.51

▲ +0.00%

Market Cap $243.97M · Vol 2.41M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$243.97M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

56.36

Momentum

Beta

0.43

vs Market

52W High

$0.58

10.68% below

52W Low

$0.08

635.32% above

Volume

2.41M

Avg 2.24M

P/B

1.99

Price-to-book

ROE

N/A

Return on equity

Free Float

70.11%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Starpharma Holdings Ltd (SPL.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SPL.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.23%

-1.43%

+12.76%

+51.88%

YTD

+106.72%

+495.36%

+380.29%

-41.17%

Financials & Valuation

TTM · Annual

Total Revenue	$3.23M
Net Income	$-6,573,406.00
Revenue Growth (YoY)	+473.73%
Gross Margin	75.08%
Operating Margin	-298.31%
Net Profit Margin	-203.38%
ROE	N/A
ROA · ROIC	-32.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7.67
P/B	1.99
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	477.05M

Technical Indicators

50-Day SMA	$0.50
200-Day SMA	$0.37
RSI (14)	56.36
Beta	0.43
52-Week High	$0.58
52-Week Low	$0.08

Volume Today	2.41M
Avg Daily Volume (30D)	2.24M
Relative Volume	1.08x
Volatility (10D)	61.91
Volatility (30D)	46.03
Free Float	70.11%

Analyst Consensus

BUY

Current Price $0.51

Mean Target $0.54

52W Low$0.08 52W High$0.58

Current

Target

$0.08 $0.58

Current Analyst target

+4.86% upside potential · 1 analysts

Identifiers

ExchangeASX

FIGIBBG001SFBLL1

ISINAU000000SPL0

CountryAustralia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateAug 26, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.